46,XX difference of sex development

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:2982
Who is this for?
Show terms as
4Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

46,XX difference of sex development (46,XX DSD), also known as 46,XX testicular disorder of sex development or 46,XX sex reversal, is a rare condition in which an individual has a female chromosomal complement (46,XX) but develops male or ambiguous external genitalia. This condition encompasses a spectrum of presentations, including 46,XX testicular DSD (formerly called XX male syndrome) and 46,XX ovotesticular DSD. The underlying mechanisms vary and may include translocation of the SRY gene (the sex-determining region of the Y chromosome) onto an X chromosome or an autosome, or mutations in other genes involved in sex determination such as SOX9, SOX3, RSPO1, or WNT4. In SRY-positive cases, individuals typically present as phenotypic males with small testes, azoospermia, and infertility, often diagnosed in adulthood. In SRY-negative cases, ambiguous genitalia may be present at birth, and the condition may be identified during the neonatal period. The condition primarily affects the reproductive and endocrine systems. Key clinical features can include ambiguous or male-appearing external genitalia, gynecomastia (breast development), small testes, hypospadias, infertility, and variable degrees of virilization. Some individuals may have ovotestes (gonads containing both ovarian and testicular tissue). Hormonal profiles may show elevated gonadotropins and low testosterone levels, similar to patterns seen in Klinefelter syndrome. Psychosocial support and appropriate gender identity assessment are important components of care. Management is multidisciplinary and individualized, involving endocrinologists, urologists, psychologists, and geneticists. Treatment may include hormone replacement therapy (testosterone supplementation in those raised male, or estrogen in those raised female), surgical correction of genital ambiguity if desired, and gonadal monitoring due to a potential risk of gonadal tumors in certain subtypes. Genetic counseling is recommended for affected individuals and their families. There is no cure, but with appropriate medical and psychological support, individuals can lead healthy lives.

Also known as:

Inheritance

Variable

Can be inherited in different ways depending on the underlying gene

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

FDA & Trial Timeline

9 events
Apr 2026Polycystic Ovary Syndrome in Type 1 Diabetes

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

TrialNOT YET RECRUITING
Jan 2026Effect of Magnesium and Levocarnitine on Metabolic and Clinical Outcomes in Women With Polycystic Ovarian Syndrome (PCOS)

Behnood Abbasi — NA

TrialRECRUITING
Jan 2026Combined Use of Machine Learning and Metabolomics to Improve the Diagnosis and Management of Hyperandrogenism

Assistance Publique - Hôpitaux de Paris

TrialNOT YET RECRUITING
Feb 2024Cardiovascular and Endothelial Markers During OGTT Before and at Six and Twelve Months Post-treatment in Women With PCOS

Attikon Hospital

TrialRECRUITING
Nov 2021Does Spironolactone Normalize Sleep-wake Luteinizing Hormone Pulse Frequency in Pubertal Girls With Hyperandrogenism?

University of Virginia — EARLY_PHASE1

TrialRECRUITING
Apr 2021FEmale Metabolic Risk and Androgens: an Irish Longitudinal (FEMAIL) Study

Royal College of Surgeons, Ireland

TrialRECRUITING
Jan 2020Body Fat as Determinant of Female Gonadal Dysfunction

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

TrialRECRUITING
Feb 2012Offspring Born to Mothers With Polycystic Ovary Syndrome in Guangzhou Cohort Study

Guangzhou Women and Children's Medical Center

TrialRECRUITING
Jun 2008Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism

University of Virginia — EARLY_PHASE1

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for 46,XX difference of sex development.

View clinical trials →

No actively recruiting trials found for 46,XX difference of sex development at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the 46,XX difference of sex development community →

Specialists

4 foundView all specialists →
RP
Renata Świątkowska-Stodulska, MD PhD
Specialist
PI on 2 active trials
CM
Christine Burt Solorzano, MD
Specialist
PI on 3 active trials
MM
Manuel Luque-Ramírez, PhD, MD, MBA
Specialist
PI on 2 active trials

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to 46,XX difference of sex development.

Search all travel grants →NORD Financial Assistance ↗

Community

Open 46,XX difference of sex developmentForum →

No community posts yet. Be the first to share your experience with 46,XX difference of sex development.

Start the conversation →

Latest news about 46,XX difference of sex development

Disease timeline:

New recruiting trial: Body Fat as Determinant of Female Gonadal Dysfunction

A new clinical trial is recruiting patients for 46,XX difference of sex development

New recruiting trial: Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism

A new clinical trial is recruiting patients for 46,XX difference of sex development

New recruiting trial: Does Spironolactone Normalize Sleep-wake Luteinizing Hormone Pulse Frequency in Pubertal Girls With Hyperandrogenism?

A new clinical trial is recruiting patients for 46,XX difference of sex development

New recruiting trial: Offspring Born to Mothers With Polycystic Ovary Syndrome in Guangzhou Cohort Study

A new clinical trial is recruiting patients for 46,XX difference of sex development

New recruiting trial: Effect of Magnesium and Levocarnitine on Metabolic and Clinical Outcomes in Women With Polycystic Ovarian Syndrome (PCOS)

A new clinical trial is recruiting patients for 46,XX difference of sex development

New recruiting trial: FEmale Metabolic Risk and Androgens: an Irish Longitudinal (FEMAIL) Study

A new clinical trial is recruiting patients for 46,XX difference of sex development

New recruiting trial: Acupuncture or Metformin for Insulin Resistance in Women With PCOS

A new clinical trial is recruiting patients for 46,XX difference of sex development

New recruiting trial: Cardiovascular and Endothelial Markers During OGTT Before and at Six and Twelve Months Post-treatment in Women With PCOS

A new clinical trial is recruiting patients for 46,XX difference of sex development

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about 46,XX difference of sex development

What is 46,XX difference of sex development?

46,XX difference of sex development (46,XX DSD), also known as 46,XX testicular disorder of sex development or 46,XX sex reversal, is a rare condition in which an individual has a female chromosomal complement (46,XX) but develops male or ambiguous external genitalia. This condition encompasses a spectrum of presentations, including 46,XX testicular DSD (formerly called XX male syndrome) and 46,XX ovotesticular DSD. The underlying mechanisms vary and may include translocation of the SRY gene (the sex-determining region of the Y chromosome) onto an X chromosome or an autosome, or mutations in o

Which specialists treat 46,XX difference of sex development?

4 specialists and care centers treating 46,XX difference of sex development are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.